(OTC: HIRU) Posts Tremendous Gains in 2009
March 08 2010 - 7:15AM
Marketwired
Hiru Corporation (PINKSHEETS: HIRU) announced earlier this month
that their subsidiary Jiangxi RongYu Pharmaceuticals, posted over
$4 million in gross profits on $24 million in gross revenues.
Jiangxi RongYu Pharmaceutical Group Co., Ltd is a leader in the
Chinese naturopathic medicine market. Naturopathic medicine is a
branch of medicine in which a variety of natural medicines and
treatments are used to heal illness. China currently holds over 10%
of this market, approximately $8 billion, with an expected doubling
of the market in the next 5 years.
Jiangxi RongYu is in a position to capitalize on the growth with
recent announcements that several of its products have been added
to China's National Essential Drugs List. All medicines placed on
this list must be available to doctors and in stock in pharmacies
and county hospitals throughout the country of China.
For more information, please visit
www.minamargroup.net/our_clients.html
Other active stocks are Eli Lilly & Co (NYSE: LLY) American
Oriental Bioengineering (NYSE: AOB) and Dana Resources (PINKSHEETS:
DANR)
Information, opinions and analysis contained herein are based on
sources believed to be reliable, but no representation, expressed
or implied, is made as to its accuracy, completeness or
correctness. The opinions contained herein reflect our current
judgment and are subject to change without notice. We accept no
liability for any losses arising from an investor's reliance on or
use of this report. This report is for information purposes only,
and is neither a solicitation to buy nor an offer to sell
securities. A third party has hired and paid IO News Wire twelve
hundred and ninety five dollars for the publication and circulation
of this news release. Certain information included herein is
forward-looking within the meaning of the Private Securities
Litigation Reform Act of 1995, including, but not limited to,
statements concerning manufacturing, marketing, growth, and
expansion. Such forward-looking information involves important
risks and uncertainties that could affect actual results and cause
them to differ materially from expectations expressed herein. We
have no ownership of equity, no representation; do no trading of
any kind and send no faxes or emails.
Contact: Eric Jensen www.ionewswire.com 516.942.4910
Dana Resources (CE) (USOTC:DANR)
Historical Stock Chart
From Dec 2024 to Jan 2025
Dana Resources (CE) (USOTC:DANR)
Historical Stock Chart
From Jan 2024 to Jan 2025